Related Experiment Video
Updated: Dec 4, 2025

07:45
An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
8.3K
Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher disease
Grant Bonesteele1, J Jay Gargus1,2, Emily Curtin1
1Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California, Irvine, United States of America.
Molecular Genetics and Metabolism Reports
|October 26, 2020
Summary
Gaucher disease type 1 (GD1) is linked to increased cancer risk, particularly non-Hodgkin's lymphoma (NHL). This study examines GD1 patients with NHL, discussing treatment outcomes and the disease's association with malignancies.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Gaucher disease type 1 (GD1) is a common lysosomal storage disease with varied presentation.
- GD1 patients exhibit an elevated risk for certain malignancies, including non-Hodgkin's lymphoma (NHL) and multiple myeloma.
- The Ashkenazi Jewish population has a higher prevalence of GD1.
Purpose of the Study:
- To describe cases of GD1 patients diagnosed with diffuse large B-cell lymphoma (DLBCL).
- To discuss the relationship between GD1 and NHL.
- To review recent findings on lyso-GL1 and its role in NHL and multiple myeloma development.
Main Methods:
- Case report of two Ashkenazi Jewish males with GD1 and DLBCL.
- Review of literature and meta-analysis of GD1 and NHL.
- Discussion of enzyme replacement therapy (ERT) and other treatments.
Main Results:
- One patient developed DLBCL after starting ERT for GD1, relapsed, and succumbed to complications post-transplant.
- Another patient diagnosed with DLBCL at age 22, later treated for GD1, remains in lymphoma remission.
- The study will elaborate on a meta-analysis of GD1 and NHL incidence.
Conclusions:
- GD1 is associated with an increased risk of NHL and multiple myeloma.
- Understanding this association is crucial for patient management and risk stratification.
- Further research into lyso-GL1 may elucidate mechanisms linking GD1 to lymphomagenesis.

